Inflammatory Myofibroblastic Tumor of the Lung: A Report of a Rare Case
- PMID: 39105041
- PMCID: PMC11298322
- DOI: 10.7759/cureus.63892
Inflammatory Myofibroblastic Tumor of the Lung: A Report of a Rare Case
Abstract
The uncommon and mysterious pulmonary inflammatory myofibroblastic tumor (PIMT) primarily affects children and young people. PIMT is characterized by the proliferation of myofibroblastic spindle cells mixed with inflammatory cells. It can resemble both benign and malignant disorders, both radiographically and clinically. PIMT typically manifests as a solitary lung tumor. The genesis of the tumor is linked to genetic anomalies, including those related to the ALK gene (anaplastic lymphoma kinase); nonetheless, some cases are not ALK-positive, indicating genetic variability. Clinically, patients may have non-specific symptoms such as cough, chest pain, or hemoptysis, or they may not exhibit any symptoms at all. In these cases, imaging tests may unintentionally reveal unrelated conditions. From a histopathological perspective, PIMT is characterized by a heterogeneous cellular makeup, encompassing lymphocytes, myofibroblasts, plasma cells, and histiocytes, which generally exhibit a fascicular or storiform pattern. The diagnosis is verified using immunohistochemical labeling, molecular research, and histological examination. The cornerstone of treatment is still surgical resection, which has a good prognosis and a low recurrence rate. On the other hand, specific treatments, such as ALK inhibitors, have shown promise for incurable or recurring instances. Even though PIMT usually has a benign history, it is important to comprehend its biological behavior and molecular foundations for precise diagnosis and efficient management. This underscores the need for additional study into the pathophysiology and potential treatments of PIMT. This report presents a case of a 53-year-old female who presented with complaints of breathlessness and chest pain and was diagnosed with the condition accidentally.
Keywords: alk-1; imt; pleural; pseudotumor; pulmonary neoplasm.
Copyright © 2024, Bhawani et al.
Conflict of interest statement
Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Figures



References
-
- Inflammatory myofibroblastic tumours: where are we now? Gleason BC, Hornick JL. J Clin Pathol. 2008;61:428–437. - PubMed
-
- What do we know about inflammatory myofibroblastic tumors? - a systematic review. Siemion K, Reszec-Gielazyn J, Kisluk J, Roszkowiak L, Zak J, Korzynska A. https://doi.org/10.1016/j.advms.2022.02.002. Adv Med Sci. 2022;67:129–138. - PubMed
-
- Inflammatory myofibroblastic tumor: a rare tumor of the lung. İçmeli ÖS, Alpay LA, Gündoğuş B, Türker H, Şen A. https://doi.org/10.3402/ecrj.v1.25390 Eur Clin Respir J. 2014;1 - PMC - PubMed
-
- Inflammatory myofibroblastic tumor of the lung. Khatri A, Agrawal A, Sikachi RR, Mehta D, Sahni S, Meena N. https://doi.org/10.5603/ARM.2018.0007. Adv Respir Med. 2018;86:27–35. - PubMed
-
- Inflammatory myofibroblastic tumor of lung (pseudotumor of the lung) Mahale A, Venugopal A, Acharya V, Kishore MS, Shanmuganathan A, Dhungel K. Indian J Radiol Imaging. 2006;16:207–210.
Publication types
LinkOut - more resources
Full Text Sources